Table 2.
KSADS-PL current diagnoses, psychiatric pharmacotherapy and other medications potentially affecting weight of participants with full or subthreshold avoidant/restrictive food intake disorder with vs. without overweight/obesity
| Healthy weight (n=12) | Overweight/obesity (n=11) | |
|---|---|---|
|
| ||
| Psychiatric comorbidities (current) | ||
| Major depressive disorder | 0 | 2 (18%) |
| Generalized anxiety disorder | 3 (25%) | 6 (54%) |
| Panic disorder | 1 (8.3%) | 5 (45%) |
| Social anxiety disorder | 1 (8.3%) | 1 (9%) |
| Autism spectrum disorder | 1 (8.3%) | 1 (9%) |
| Obsessive compulsive disorder | 1 (8.3%) | 0 |
| ADHD | 4 (33%) | 1 (9%) |
| More than one psychiatric diagnosis (not including ARFID) | 2 (17%) | 4 (36%) |
| Psychiatric pharmacotherapy | ||
| Antidepressantsa | 5 (42%) | 5 (45%) |
| Antipsychoticsb | 2 (17%) | 0 |
| Anxiolyticsc | 1 (8.3%) | 0 |
| Stimulantsd | 4 (33%) | 0 |
| More than one psychiatric medication | 5 (42%) | 1 (9%) |
| Other medications | ||
| Metformine | 1 (8.3%) | 0 |
| Cyproheptadinef | 1 (8.3%) | 0 |
Abbreviations: KSADS-PL, Kiddie Schedule for Affective Disorders and Schizophrenia for School Age Children - Present and Lifetime Version.
Antidepressants included sertraline, fluoxetine, citalopram, bupropion and trazadone.
Antipsychotics included risperidone and olanzapine and were specifically prescribed for the treatment of ARFID, to facilitate eating and alleviate the cognitive symptoms of ARFID (Brewerton & D’Agostino, 2017).
Anxiolytics included clonazepam.
Stimulants included methylphenidate and dextroamphetamine/amphetamine.
Metformin was prescribed to address weight gain caused by antipsychotic treatment.
Cyproheptadine prescribed to increase appetite (Harrison et al., 2019).